Levetiracetam ratiopharm 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0039/G 
This was an application for a group of variations. 
22/06/2023 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0038 
B.IV.1.a.1 - Change of a measuring or administration 
16/09/2022 
n/a 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
IB/0037/G 
This was an application for a group of variations. 
15/07/2022 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IA/0036 
A.5.b - Administrative change - Change in the name 
15/06/2022 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
Page 2/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0035 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/06/2022 
26/05/2023 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0034 
B.II.a.3.a.1 - Changes in the composition 
20/05/2022 
n/a 
(excipients) of the finished product - Changes in 
components of the flavouring or colouring system - 
Addition , deletion or replacement 
IA/0033/G 
This was an application for a group of variations. 
19/11/2021 
n/a 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0032/G 
This was an application for a group of variations. 
15/09/2021 
n/a 
Page 3/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0031/G 
This was an application for a group of variations. 
25/05/2021 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0030 
C.I.2.a - Change in the SPC, Labelling or PL of a 
21/05/2021 
14/06/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 4/13 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0029/G 
This was an application for a group of variations. 
11/01/2021 
14/06/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0028 
B.II.b.4.z - Change in the batch size (including batch 
19/11/2020 
n/a 
size ranges) of the finished product - Other variation 
IB/0027/G 
This was an application for a group of variations. 
29/09/2020 
n/a 
B.II.a.2.z - Change in the shape or dimensions of the 
pharmaceutical form - Other variation 
IAIN/0026/G 
This was an application for a group of variations. 
20/03/2020 
n/a 
B.IV.1.a.1 - Change of a measuring or administration 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
B.IV.1.a.1 - Change of a measuring or administration 
device - Addition or replacement of a device which is 
Page 5/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
not an integrated part of the primary packaging - 
Device with CE marking 
B.IV.1.a.1 - Change of a measuring or administration 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
IB/0025 
C.I.2.a - Change in the SPC, Labelling or PL of a 
07/02/2020 
29/01/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0024/G 
This was an application for a group of variations. 
18/12/2019 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
Page 6/13 
 
 
 
 
 
 
 
 
 
 
 
from an already approved manufacturer 
IB/0023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/09/2019 
24/10/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0022 
B.II.b.1.a - Replacement or addition of a 
14/05/2019 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0021/G 
This was an application for a group of variations. 
22/11/2018 
24/10/2019 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 7/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
IB/0020 
B.II.e.1.a.2 - Change in immediate packaging of the 
19/12/2017 
n/a 
finished product - Qualitative and quantitative 
composition - Semi-solid and non-sterile liquid 
pharmaceutical forms 
IAIN/0019 
B.III.1.a.3 - Submission of a new/updated or 
07/12/2017 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
N/0018 
Minor change in labelling or package leaflet not 
10/08/2017 
20/12/2017 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
IA/0017 
A.7 - Administrative change - Deletion of 
26/04/2017 
n/a 
manufacturing sites 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/02/2017 
20/12/2017 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0016 
C.I.z - Changes (Safety/Efficacy) of Human and 
20/01/2017 
20/12/2017 
PL 
Veterinary Medicinal Products - Other variation 
R/0014 
Renewal of the marketing authorisation. 
25/02/2016 
28/04/2016 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II and Labelling 
the CHMP considered that the benefit-risk balance of 
Page 8/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0013 
A.5.b - Administrative change - Change in the name 
30/09/2015 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0012/G 
This was an application for a group of variations. 
30/09/2015 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0011/G 
This was an application for a group of variations. 
28/08/2014 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.2.a - Change to importer, batch release 
Levetiracetam ratiopharm in the approved indications 
remain favourable and therefore recommended the renewal 
of the marketing authorisation with unlimited validity. 
Page 9/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IAIN/0010/G 
This was an application for a group of variations. 
15/08/2014 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.III.1.a.1 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IB/0009/G 
This was an application for a group of variations. 
24/04/2014 
11/12/2014 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 10/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0008 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/12/2013 
11/12/2014 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0007/G 
This was an application for a group of variations. 
18/11/2013 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0006 
C.I.z - Changes (Safety/Efficacy) of Human and 
20/06/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IB/0005 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/07/2012 
10/09/2012 
SmPC, Annex 
The Product information for this generic medicinal product 
generic/hybrid/biosimilar products following 
II, Labelling 
is up-dated in order to follow the update of section 4.8 of 
assessment of the same change for the reference 
and PL 
the SmPC by the originator Keppra 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
(EMEA/H/C/000277/II/0131) to add ‘panic attack’ as an 
undesirable effect. The PIL is updated accordingly. In 
addition, the description of pancytopenia, erythema 
multiforme, Stevens-Johnsons syndrome and toxic 
Page 11/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
epidermal necrolysis in section 4 of the Package Leaflet was 
updated. Furthermore changes relating to the 
implementation of the latest QRD template have been 
introduced, as requested by CHMP and in line with the 
originator.  
All changes have been made in line with the originator 
product. 
Moreover, a copy and paste error in the Dutch version of 
the PIL for each strength (250 mg, 500 mg, 750 mg, 1000 
mg) has been corrected to bring in line with the adopted EN 
version. 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
17/01/2012 
10/09/2012 
SmPC, 
Update of Summary of Product Characteristics, Labelling 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IB/0003 
B.II.b.1.e - Replacement or addition of a 
26/10/2011 
n/a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
Labelling and 
and Package Leaflet to align with the reference medicinal 
PL 
product Keppra. The section 4.8 of the SmPC was updated 
in line with the revised SmPC Guideline (September 2009); 
the following subsections have been revised: Summary of 
the safety profile, Tabulated list of adverse reactions and 
Paediatric population. As a result frequencies of some 
adverse reactions have been changed. Moreover, two new 
adverse reactions have been added: lethargy and muscular 
weakness. The package leaflet was updated accordingly. 
Furthermore, changes to the labelling to clarify the 
differentiation of the three oral presentations and minor 
editorial updates throughout the PI were introduced. 
Additionally the MAH updated the list of local 
representatives in the PL. 
Page 12/13 
 
 
 
 
 
 
 
 
packaging, for non-sterile medicinal products 
IA/0002/G 
This was an application for a group of variations. 
11/10/2011 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.a - Change to batch release arrangements 
and quality control testing of the FP - Replacement 
or addition of a site where batch control/testing 
takes place 
IA/0001 
B.II.d.1.d - Change in the specification parameters 
11/10/2011 
n/a 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter (e.g. deletion 
of an obsolete parameter 
Page 13/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
